{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:59:23Z","timestamp":1782975563666,"version":"3.54.5"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072712"],"award-info":[{"award-number":["82072712"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Suzhou Science and Technology Development Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In this study, we investigated the expression patterns, biological functions, and molecular mechanisms of Proline-rich \u03b3-carboxylated Gla protein 1 (PRRG1) in pancreatic cancer pathogenesis. Our bioinformatics analysis revealed that PRRG1 expression is markedly upregulated in human PC tissues compared to normal pancreatic tissues, with elevated levels significantly correlating with poor prognosis and advanced histological grade. We verified the high expression of PRRG1 in pancreatic cancer tissue specimens and pancreatic cancer cell lines. Using established PC cell lines (CFPAC-1 and PATU-8988T), we demonstrated that shRNA-mediated PRRG1 silencing effectively suppressed malignant phenotypes, including cell viability, proliferation, migration, and invasion in vitro. Conversely, lentivirus-induced PRRG1 overexpression enhanced these oncogenic behaviors. RNA-sequencing analysis identified the PI3K-Akt signaling pathway as a key downstream effector of PRRG1, with pathway activation status directly correlating with PRRG1 expression levels. Mechanistically, we identified KLF4 as a critical transcription factor binding to the PRRG1 promoter region. In vivo, PRRG1 knockdown inhibited tumor growth and PI3K-Akt activation in subcutaneous xenograft models, while PRRG1 overexpression accelerated tumor progression. Low-dose warfarin (2uM) decreased the levels of PRRG1 and GAS6\/AXL axis, markedly suppressed the pro-tumorigenic effects driven by PRRG1 overexpression in vitro and in vivo. Notably, single-cell sequencing analysis revealing high PRRG1 expression specifically in PC epithelial cells. These PRRG1-positive epithelial cells not only exhibited enriched PI3K-Akt signaling activity but also showed significant interactions with macrophages and endothelial cells, which were further validated in immunocompetent models in vivo. However, warfarin effectively reversed the PRRG1 overexpression\u2013driven changes in TME. In conclusion, our findings establish PRRG1 as a key driver of pancreatic cancer progression through PI3K\/Akt pathway activation and KLF4-mediated transcriptional regulation. PRRG1 facilitates the establishment of a pro-tumorigenic and immunosuppressive TME in PC. Low-dose warfarin significantly suppressed the pro-tumorigenic effects and the PRRG1 overexpression\u2013driven alterations in the tumor immune microenvironment.<\/jats:p>","DOI":"10.1038\/s41419-026-08832-9","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T13:43:46Z","timestamp":1778420626000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of PRRG1 as a possible molecular target of pancreatic cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4560-2553","authenticated-orcid":false,"given":"Jia-Jie","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4784-3876","authenticated-orcid":false,"given":"Xiao-Ren","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian-Hui","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8351-4282","authenticated-orcid":false,"given":"Yuan-Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1453-8664","authenticated-orcid":false,"given":"Min-Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,10]]},"reference":[{"key":"8832_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"8832_CR2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","volume":"164","author":"EM Stoffel","year":"2023","unstructured":"Stoffel EM, Brand RE, Goggins M. Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology. 2023;164:752\u201365.","journal-title":"Gastroenterology"},{"key":"8832_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","volume":"163","author":"LD Wood","year":"2022","unstructured":"Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology. 2022;163:386\u2013402.e1.","journal-title":"Gastroenterology"},{"key":"8832_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326:851\u201362.","journal-title":"JAMA"},{"key":"8832_CR5","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1200\/JCO.22.00432","volume":"40","author":"W Attaallah","year":"2022","unstructured":"Attaallah W. Neoadjuvant chemoradiotherapy for resectable and borderline resectable pancreatic cancer. J Clin Oncol. 2022;40:3346.","journal-title":"J Clin Oncol"},{"key":"8832_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","volume":"17","author":"AN Hosein","year":"2020","unstructured":"Hosein AN, Brekken RA-O, Maitra AA-O. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17:487\u2013505.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8832_CR7","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","volume":"38","author":"AS Bear","year":"2020","unstructured":"Bear AS, Vonderheide RH, O\u2019Hara MH. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell. 2020;38:788\u2013802.","journal-title":"Cancer Cell"},{"key":"8832_CR8","first-page":"00111","volume":"S1658-3876","author":"L Suleiman","year":"2021","unstructured":"Suleiman L, Muataz Y, N\u00e9grier C, Boukerche H. Protein S-mediated signal transduction pathway regulates lung cancer cell proliferation, migration and angiogenesis. Hematol Oncol Stem Cell Ther. 2021;S1658-3876:00111\u20134.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"8832_CR9","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.3390\/cimb46040205","volume":"46","author":"AA-O Joussaume","year":"2024","unstructured":"Joussaume AA-O, Kanthou CA-O, Pardo OE, Karayan-Tapon L, Benzakour O, Dkhissi F. The vitamin K-dependent anticoagulant factor, protein S, regulates vascular permeability. Curr Issues Mol Biol. 2024;46:3278\u201393.","journal-title":"Curr Issues Mol Biol"},{"key":"8832_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1090-3","volume":"18","author":"C Zhu","year":"2019","unstructured":"Zhu C, Wei Y, Wei X. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019;18:153.","journal-title":"Mol Cancer"},{"key":"8832_CR11","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1158\/0008-5472.CAN-14-2887-T","volume":"75","author":"A Kirane","year":"2015","unstructured":"Kirane A, Ludwig KF, Sorrelle N, Haaland G, Sandal T, Ranaweera R, et al. Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis. Cancer Res. 2015;75:3699\u2013705.","journal-title":"Cancer Res"},{"key":"8832_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0083-6729(07)00008-8","volume":"78","author":"PK Bandyopadhyay","year":"2008","unstructured":"Bandyopadhyay PK. Vitamin K-dependent gamma-glutamylcarboxylation: an ancient posttranslational modification. Vitam Horm. 2008;78:157\u201384.","journal-title":"Vitam Horm"},{"key":"8832_CR13","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.3390\/ijms23105759","volume":"23","author":"K Berkner","year":"2022","unstructured":"Berkner K, Runge K. Vitamin K-dependent protein activation: normal gamma-glutamyl carboxylation and disruption in disease. Int J Mol Sci. 2022;23:5759.","journal-title":"Int J Mol Sci"},{"key":"8832_CR14","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.molmed.2022.07.002","volume":"28","author":"J Welsh","year":"2022","unstructured":"Welsh J, Bak MJ, Narvaez CJ. New insights into vitamin K biology with relevance to cancer. Trends Mol Med. 2022;28:864\u201381.","journal-title":"Trends Mol Med"},{"key":"8832_CR15","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.critrevonc.2013.07.004","volume":"88","author":"L Suleiman","year":"2013","unstructured":"Suleiman L, N\u00e9grier C, Boukerche H. Protein S: a multifunctional anticoagulant vitamin K-dependent protein at the crossroads of coagulation, inflammation, angiogenesis, and cancer. Crit Rev Oncol Hematol. 2013;88:637\u201354.","journal-title":"Crit Rev Oncol Hematol"},{"key":"8832_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0769-1","volume":"17","author":"G Wu","year":"2018","unstructured":"Wu G, Ma Z, Cheng Y, Hu W, Deng C, Jiang S, et al. Targeting Gas6\/TAM in cancer cells and tumor microenvironment. Mol Cancer. 2018;17:20.","journal-title":"Mol Cancer"},{"key":"8832_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1022-2","volume":"18","author":"K Myers","year":"2019","unstructured":"Myers K, Amend SR, Pienta KJ. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment. Mol Cancer. 2019;18:94.","journal-title":"Mol Cancer"},{"key":"8832_CR18","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41571-023-00813-7","volume":"20","author":"D DeRyckere","year":"2023","unstructured":"DeRyckere D, Huelse J, Earp HS, Graham D. TAM family kinases as therapeutic targets at the interface of cancer and immunity. Nat Rev Clin Oncol. 2023;20:755\u201379.","journal-title":"Nat Rev Clin Oncol"},{"key":"8832_CR19","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1182\/blood-2017-09-804666","volume":"131","author":"MA Rishavy","year":"2018","unstructured":"Rishavy MA, Hallgren KW, Wilson L, Singh S, Runge K, Berkner K. Warfarin alters vitamin K metabolism: a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase. Blood. 2018;131:2826\u201335.","journal-title":"Blood"},{"key":"8832_CR20","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1182\/blood-2018-01-830901","volume":"132","author":"S Wu","year":"2018","unstructured":"Wu S, Chen X, Jin DY, Stafford DW, Pedersen LA-O, Tie JA-O. Warfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibition. Blood. 2018;132:647\u201357.","journal-title":"Blood"},{"key":"8832_CR21","doi-asserted-by":"publisher","first-page":"9058","DOI":"10.1073\/pnas.94.17.9058","volume":"94","author":"JD Kulman","year":"1997","unstructured":"Kulman JD, Harris JE, Haldeman BA, Davie EW. Primary structure and tissue distribution of two novel proline-rich gamma-carboxyglutamic acid proteins. Proc Natl Acad Sci USA. 1997;94:9058\u201362.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8832_CR22","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1073\/pnas.98.4.1370","volume":"98","author":"JD Kulman","year":"2001","unstructured":"Kulman JD, Harris JE, Xie L, Davie EW. Identification of two novel transmembrane gamma-carboxyglutamic acid proteins expressed broadly in fetal and adult tissues. Proc Natl Acad Sci USA. 2001;98:1370\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8832_CR23","doi-asserted-by":"publisher","first-page":"8767","DOI":"10.1073\/pnas.0703195104","volume":"104","author":"JD Kulman","year":"2007","unstructured":"Kulman JD, Harris JE, Xie L, Davie EW. Proline-rich Gla protein 2 is a cell-surface vitamin K-dependent protein that binds to the transcriptional coactivator Yes-associated protein. Proc Natl Acad Sci USA. 2007;104:8767\u201372.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8832_CR24","doi-asserted-by":"publisher","first-page":"25908","DOI":"10.1074\/jbc.M113.484683","volume":"288","author":"MN Yazicioglu","year":"2013","unstructured":"Yazicioglu MN, Monaldini L, Chu K, Khazi FR, Murphy SL, Huang H, et al. Cellular localization and characterization of cytosolic binding partners for Gla domain-containing proteins PRRG4 and PRRG2. J Biol Chem. 2013;288:25908\u201314.","journal-title":"J Biol Chem"},{"key":"8832_CR25","doi-asserted-by":"publisher","first-page":"7196","DOI":"10.1038\/s41388-020-01494-7","volume":"39","author":"L Zhang","year":"2020","unstructured":"Zhang L, Qin Y, Wu G, Wang J, Cao J, Wang Y, et al. PRRG4 promotes breast cancer metastasis through the recruitment of NEDD4 and downregulation of Robo1. Oncogene. 2020;39:7196\u2013208.","journal-title":"Oncogene"},{"key":"8832_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03178-0","volume":"23","author":"Y Wang","year":"2023","unstructured":"Wang Y, Wang J, Chen L, Chen Z, Wang T, Xiong S, et al. PRRG4 regulates mitochondrial function and promotes migratory behaviors of breast cancer cells through the Src-STAT3-POLG axis. Cancer Cell Int. 2023;23:323.","journal-title":"Cancer Cell Int"},{"key":"8832_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-1908-1","volume":"17","author":"X Sun","year":"2019","unstructured":"Sun X, Liu X, Xia M, Shao Y, Zhang XD. Multicellular gene network analysis identifies a macrophage-related gene signature predictive of therapeutic response and prognosis of gliomas. J Transl Med. 2019;17:159.","journal-title":"J Transl Med"},{"key":"8832_CR28","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1093\/carcin\/bgv112","volume":"36","author":"H Zhu","year":"2015","unstructured":"Zhu H, Han C, Wu T. MiR-17-92 cluster promotes hepatocarcinogenesis. Carcinogenesis. 2015;36:1213\u201322.","journal-title":"Carcinogenesis"},{"key":"8832_CR29","doi-asserted-by":"publisher","first-page":"e0241924","DOI":"10.1371\/journal.pone.0241924","volume":"15","author":"W Mo","year":"2020","unstructured":"Mo W, Ding Y, Zhao S, Zou D, Ding XA-O. Identification of a 6-gene signature for the survival prediction of breast cancer patients based on integrated multi-omics data analysis. PLoS One. 2020;15:e0241924.","journal-title":"PLoS One"},{"key":"8832_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70191","volume":"15","author":"Z Wu","year":"2025","unstructured":"Wu Z, Ye Q, Zhang S, Hu LP, Wang XQ, Yao LL, et al. Vitamin K-dependent gamma-carboxyglutamic acid protein 1 promotes pancreatic ductal adenocarcinoma progression through stabilizing oncoprotein KRAS and tyrosine kinase receptor EGFR. Clin Transl Med. 2025;15:e70191.","journal-title":"Clin Transl Med"},{"key":"8832_CR31","first-page":"1001","volume":"3","author":"TD Schmittgen","year":"2001","unstructured":"Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2001;3:1001\u20138.","journal-title":"Nat Protoc"},{"key":"8832_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.","journal-title":"Nucleic Acids Res"},{"key":"8832_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn6928","volume":"8","author":"J Yao","year":"2022","unstructured":"Yao J, Wu X, Yu Q, Yang S, Yuan J, Zhang ZQ, et al. The requirement of phosphoenolpyruvate carboxykinase 1 for angiogenesis in vitro and in vivo. Sci Adv. 2022;8:eabn6928.","journal-title":"Sci Adv"},{"key":"8832_CR34","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1002\/j.1460-2075.1996.tb00911.x","volume":"15","author":"GJ Brunn","year":"1996","unstructured":"Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC Jr, Abraham RT. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 1996;15:5256\u201367.","journal-title":"EMBO J"},{"key":"8832_CR35","doi-asserted-by":"publisher","first-page":"D870","DOI":"10.1093\/nar\/gkac947","volume":"51","author":"C Hu","year":"2023","unstructured":"Hu C, Li T, Xu Y, Zhang X, Li F, Bai J, et al. CellMarker 2.0: an updated database of manually curated cell markers in human\/mouse and web tools based on scRNA-seq data. Nucleic Acids Res. 2023;51:D870\u2013D6.","journal-title":"Nucleic Acids Res"},{"key":"8832_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122838","volume":"314","author":"S Tabe","year":"2025","unstructured":"Tabe S, Takeuchi K, Aoshima K, Okumura A, Yamamoto Y, Yanagisawa K, et al. A pancreatic cancer organoid incorporating macrophages reveals the correlation between the diversity of tumor-associated macrophages and cancer cell survival. Biomaterials. 2025;314:122838.","journal-title":"Biomaterials"},{"key":"8832_CR37","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jare.2024.01.016","volume":"67","author":"G Li","year":"2025","unstructured":"Li G, Gao J, Ding P, Gao Y. The role of endothelial cell-pericyte interactions in vascularization and diseases. J Adv Res. 2025;67:269\u201388.","journal-title":"J Adv Res"},{"key":"8832_CR38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1146\/annurev-pathmechdis-012418-013058","volume":"16","author":"S Ugel","year":"2021","unstructured":"Ugel S, Can\u00e8 S, De Sanctis F, Bronte V. Monocytes in the tumor microenvironment. Annu Rev Pathol. 2021;16:93\u2013122.","journal-title":"Annu Rev Pathol"},{"key":"8832_CR39","doi-asserted-by":"publisher","first-page":"11182","DOI":"10.3748\/wjg.v20.i32.11182","volume":"20","author":"AE Becker","year":"2014","unstructured":"Becker AE, Hernandez YG, Frucht H, Lucas AL. Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol. 2014;20:11182\u201398.","journal-title":"World J Gastroenterol"},{"key":"8832_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1053\/j.seminoncol.2014.12.002","volume":"42","author":"TP Yeo","year":"2015","unstructured":"Yeo TP. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin Oncol. 2015;42:8\u201318.","journal-title":"Semin Oncol"},{"key":"8832_CR41","doi-asserted-by":"crossref","unstructured":"Pergolizzi RG, Brower ST. Molecular targets for the diagnosis and treatment of pancreatic cancer. Int J Mol Sci. 2024;25:10843.","DOI":"10.3390\/ijms251910843"},{"key":"8832_CR42","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.3390\/cancers16101808","volume":"16","author":"O Olaoba","year":"2024","unstructured":"Olaoba O, Adelusi TI, Yang M, Maidens T, Kimchi E, Staveley-O\u2019Carroll KF, et al. Driver mutations in pancreatic cancer and opportunities for targeted therapy. Cancers. 2024;16:1808.","journal-title":"Cancers"},{"key":"8832_CR43","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-19-3724","volume":"26","author":"GM O\u2019Kane","year":"2020","unstructured":"O\u2019Kane GM, Gr\u00fcnwald B, Jang GH, Masoomian M, Picardo S, Grant R, et al. GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer. Clin Cancer Res. 2020;26:4901\u201310.","journal-title":"Clin Cancer Res"},{"key":"8832_CR44","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1158\/2159-8290.CD-20-0633","volume":"11","author":"B Flowers","year":"2021","unstructured":"Flowers B, Xu H, Mulligan A, Hanson K, Seoane J, Vogel H, et al. Cell of origin influences pancreatic cancer subtype. Cancer Discov. 2021;11:660\u201377.","journal-title":"Cancer Discov"},{"key":"8832_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2025.108946","volume":"277","author":"Y Ohara","year":"2025","unstructured":"Ohara Y, Liu H, Moreno P, Suzuki S, Hussain SP. Molecular, metabolic, and histological subtypes of pancreatic ductal adenocarcinoma and its tumor microenvironment: insights into tumor heterogeneity and clinical implications. Pharm Ther. 2025;277:108946.","journal-title":"Pharm Ther"},{"key":"8832_CR46","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","volume":"24","author":"KL Aung","year":"2018","unstructured":"Aung KL, Fischer SE, Denroche RE, Jang GH, Dodd A, Creighton S, et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin Cancer Res. 2018;24:1344\u201354.","journal-title":"Clin Cancer Res"},{"key":"8832_CR47","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","volume":"14","author":"J Dilly","year":"2024","unstructured":"Dilly J, Hoffman M, Abbassi L, Li Z, Paradiso F, Parent B, et al. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. Cancer Discov. 2024;14:2135\u201361.","journal-title":"Cancer Discov"},{"key":"8832_CR48","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s43018-021-00326-1","volume":"3","author":"C Falcomat\u00e0","year":"2022","unstructured":"Falcomat\u00e0 C, B\u00e4rthel S, Widholz S, Schneeweis C, Montero JJ, Toska A, et al. Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Nat Cancer. 2022;3:318\u201336.","journal-title":"Nat Cancer"},{"key":"8832_CR49","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1146\/annurev-physiol-020518-114515","volume":"81","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Crawford HC, Pasca di Magliano M. Epithelial-stromal interactions in pancreatic cancer. Annu Rev Physiol. 2019;81:211\u201333.","journal-title":"Annu Rev Physiol"},{"key":"8832_CR50","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.cell.2011.11.025","volume":"148","author":"AD Rhim","year":"2012","unstructured":"Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148:349\u201361.","journal-title":"Cell"},{"key":"8832_CR51","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.apsb.2018.01.008","volume":"8","author":"F Liu","year":"2018","unstructured":"Liu F, Yang X, Geng M, Huang M. Targeting ERK, an Achilles\u2019 Heel of the MAPK pathway, in cancer therapy. Acta Pharm Sin B. 2018;8:552\u201362.","journal-title":"Acta Pharm Sin B"},{"key":"8832_CR52","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6:425.","journal-title":"Signal Transduct Target Ther"},{"key":"8832_CR53","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6:402.","journal-title":"Signal Transduct Target Ther"},{"key":"8832_CR54","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1126\/science.1164368","volume":"321","author":"S Jones","year":"2008","unstructured":"Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801\u20136.","journal-title":"Science"},{"key":"8832_CR55","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.semcancer.2019.07.003","volume":"59","author":"AK Murugan","year":"2019","unstructured":"Murugan AK. mTOR: role in cancer, metastasis and drug resistance. Semin Cancer Biol. 2019;59:92\u2013111.","journal-title":"Semin Cancer Biol"},{"key":"8832_CR56","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semcancer.2022.04.002","volume":"85","author":"E Levantini","year":"2022","unstructured":"Levantini E, Maroni G, Del Re M, Tenen DG. EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol. 2022;85:253\u201375.","journal-title":"Semin Cancer Biol"},{"key":"8832_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13009","volume":"54","author":"G Liu","year":"2021","unstructured":"Liu G, Chen T, Ding Z, Wang Y, Wei Y, Wei X. Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment. Cell Prolif. 2021;54:e13009.","journal-title":"Cell Prolif"},{"key":"8832_CR58","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1038\/s41388-023-02701-x","volume":"42","author":"A Poh","year":"2023","unstructured":"Poh A, Ernst M. Functional roles of SRC signaling in pancreatic cancer: recent insights provide novel therapeutic opportunities. Oncogene. 2023;42:1786\u2013801.","journal-title":"Oncogene"},{"key":"8832_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1274209","volume":"15","author":"HH Hu","year":"2024","unstructured":"Hu HH, Wang SQ, Shang HL, Lv HF, Chen BB, Gao SG, et al. Roles and inhibitors of FAK in cancer: current advances and future directions. Front Pharmacol. 2024;15:1274209.","journal-title":"Front Pharmacol"},{"key":"8832_CR60","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.2147\/OTT.S237174","volume":"13","author":"S Mao","year":"2020","unstructured":"Mao S, Wu Y, Wang R, Guo Y, Bi D, Ma W, et al. Overexpression of GAS6 promotes cell proliferation and invasion in bladder cancer by activation of the PI3K\/AKT pathway. Onco Targets Ther. 2020;13:4813\u201324.","journal-title":"Onco Targets Ther"},{"key":"8832_CR61","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/mc.20211","volume":"46","author":"T Sawabu","year":"2007","unstructured":"Sawabu T, Seno H, Kawashima T, Fukuda A, Uenoyama Y, Kawada M, et al. Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via AKT pathway. Mol Carcinog. 2007;46:155\u201364.","journal-title":"Mol Carcinog"},{"key":"8832_CR62","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.3390\/cimb46100676","volume":"46","author":"S Gao","year":"2024","unstructured":"Gao S, Wang Y, Huang M, Guo J, Wu Z, Li J. Knockdown of Gas6 exerts anti-esophageal cancer effects by inhibiting the PI3K\/AKT pathway. Curr Issues Mol Biol. 2024;46:1349\u201311358.","journal-title":"Curr Issues Mol Biol"},{"key":"8832_CR63","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1136\/gutjnl-2013-306202","volume":"63","author":"DC Morran","year":"2014","unstructured":"Morran DC, Wu J, Jamieson NB, Mrowinska A, Kalna G, Karim SA, et al. Targeting mTOR dependency in pancreatic cancer. Gut. 2014;63:1481\u20139.","journal-title":"Gut"},{"key":"8832_CR64","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","volume":"85","author":"L Yu","year":"2022","unstructured":"Yu L, Wei J, Liu P. Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol. 2022;85:69\u201394.","journal-title":"Semin Cancer Biol"},{"key":"8832_CR65","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.gene.2017.02.025","volume":"611","author":"AM Ghaleb","year":"2017","unstructured":"Ghaleb AM, Yang VW. Kr\u00fcppel-like factor 4 (KLF4): what we currently know. Gene. 2017;611:27\u201337.","journal-title":"Gene"},{"key":"8832_CR66","doi-asserted-by":"publisher","first-page":"8843","DOI":"10.3390\/ijms21228843","volume":"21","author":"A Taracha-Wisniewska","year":"2020","unstructured":"Taracha-Wisniewska A, Kotarba G, Dworkin S, Wilanowski T. Recent discoveries on the involvement of Kr\u00fcppel-Like Factor 4 in the most common cancer types. Int J Mol Sci. 2020;21:8843.","journal-title":"Int J Mol Sci"},{"key":"8832_CR67","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s13105-015-0381-4","volume":"71","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Hao J, Zheng Y, Jing D, Shen Y, Wang J, et al. Role of Kr\u00fcppel-like factors in cancer stem cells. J Physiol Biochem. 2015;71:155\u201364.","journal-title":"J Physiol Biochem"},{"key":"8832_CR68","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1007\/s10620-024-08473-y","volume":"69","author":"L Yuan","year":"2024","unstructured":"Yuan L, Meng Y, Xiang J. KLF4 induces colorectal cancer by promoting EMT via STAT3 activation. Dig Dis Sci. 2024;69:2841\u201355.","journal-title":"Dig Dis Sci"},{"key":"8832_CR69","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1080\/10428194.2020.1869960","volume":"62","author":"M Montecillo-Aguado","year":"2021","unstructured":"Montecillo-Aguado M, Morales-Mart\u00ednez M, Huerta-Yepez SA-O, Vega MA-O. KLF4 inhibition by kenpaullone induces cytotoxicity and chemo sensitization in B-NHL cell lines via YY1 independent. Leuk Lymphoma. 2021;62:1422\u201331.","journal-title":"Leuk Lymphoma"},{"key":"8832_CR70","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ebiom.2019.05.011","volume":"44","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, Feng Z, Hu D, Yang P, Gur M, Bahar I, et al. A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy. EBioMedicine. 2019;44:98\u2013111.","journal-title":"EBioMedicine"},{"key":"8832_CR71","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.1016\/j.thromres.2021.11.004","volume":"213","author":"T Chiasakul","year":"2022","unstructured":"Chiasakul T, Zwicker JI. The impact of warfarin on overall survival in cancer patients. Thromb Res. 2022;213:S113\u2013S9.","journal-title":"Thromb Res"},{"key":"8832_CR72","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1182\/blood-2013-02-485011","volume":"123","author":"EM Battinelli","year":"2014","unstructured":"Battinelli EM, Markens BA, Kulenthirarajan RA, Machlus KR, Flaumenhaft R, Italiano JE Jr. Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response. Blood. 2014;123:101\u201312.","journal-title":"Blood"},{"key":"8832_CR73","doi-asserted-by":"publisher","first-page":"7031","DOI":"10.18632\/oncotarget.27345","volume":"10","author":"SV Novitskiy","year":"2019","unstructured":"Novitskiy SV, Zaynagetdinov R, Vasiukov G, Gutor S, Han W, Serezani A, et al. Gas6\/MerTK signaling is negatively regulated by NF-\u03baB and supports lung carcinogenesis. Oncotarget. 2019;10:7031\u201342.","journal-title":"Oncotarget"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08832-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08832-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08832-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:26:49Z","timestamp":1782970009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08832-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,10]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8832"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08832-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,10]]},"assertion":[{"value":"1 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by Ethics Committee of Affiliated Kunshan Hospital of Jiangsu University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}}],"article-number":"613"}}